Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Zhejiang Provincial Key Laboratory of Pancreatic Disease, Hangzhou, China.
State Key Laboratory of Oncogenes and Related Genes, Renji-MedX Stem Cell Research Center, Ren Ji Hospital, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200030, PR China; Med-X Research Institute, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200030, PR China.
Cancer Lett. 2022 Jan 28;525:9-21. doi: 10.1016/j.canlet.2021.10.027. Epub 2021 Oct 29.
Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer-related death among men in western countries. Androgen deprivation therapy (ADT) is considered the standard therapy for recurrent prostate cancer; however, this therapy may lead to ADT resistance and tumor progression, which seems to be regulated by epithelial-mesenchymal transition (EMT) and/or neuroendocrine differentiation (NED). In addition, recent data suggested the involvement of either adaptive or innate infiltrated immune cells in the initiation, progression, metastasis, and treatment of prostate cancer. In this review, we outlined the characteristics and roles of these immune cells in the initiation, progression, metastasis, and treatments of prostate cancer. We also summarized the current therapeutic strategies in targeting immune cells of the prostate tumor microenvironment.
前列腺癌是西方国家男性最常见的癌症和第二大癌症相关死亡原因。去势治疗（ADT）被认为是复发性前列腺癌的标准治疗方法；然而，这种治疗方法可能导致 ADT 耐药和肿瘤进展，这似乎受到上皮-间充质转化（EMT）和/或神经内分泌分化（NED）的调节。此外，最近的数据表明，适应性或固有浸润免疫细胞参与了前列腺癌的发生、发展、转移和治疗。在这篇综述中，我们概述了这些免疫细胞在前列腺癌发生、发展、转移和治疗中的特征和作用。我们还总结了目前针对前列腺肿瘤微环境中免疫细胞的治疗策略。
